Coinjection with TLR2 agonist Pam3CSK4 reduces the pathology of leishmanization in mice.

• Asıl Yazarlar: Lu Huang (Yazar), Meleana Hinchman (Yazar), Susana Mendez (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Public Library of Science (PLoS), 2015-03-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Cutaneous leishmaniasis caused by Leishmania major is an emergent, uncontrolled public health problem and there is no vaccine. A promising prophylactic approach has been immunotherapy with Toll-like receptor (TLR) agonists to enhance parasite-specific immune responses. We have previously reported th...